Expression of Concern: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

, Frontiers Editorial Office

doi:10.3389/fmed.2021.831449

GENERAL COMMENTARY article

Front. Med., 17 January 2022

Sec. Infectious Diseases: Pathogenesis and Therapy

Volume 8 - 2021 | https://doi.org/10.3389/fmed.2021.831449

Expression of Concern: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

This article is a commentary on:

RETRACTED: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
1. Read original article

Frontiers Editorial Office^*

An Expression of Concern on
Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

by McCoy, J., Goren, A., Cadegiani, F. A., Vaño-Galván, S., Kovacevic, M., Situm, M., Shapiro, J., Sinclair, R., Tosti, A., Stanimirovic, A., Fonseca, D., Dorner, E., Onety, D. C., Zimerman, R. A., and Wambier, C. G. (2021). Front. Med. 8:668698. doi: 10.3389/fmed.2021.668698

With this notice, Frontiers states its awareness of serious complaints regarding this article. This expression of concern has been posted while Frontiers investigates the allegations. The situation will be updated as soon as the investigation is complete.

This article has now been retracted. Please find the full retraction here: https://www.frontiersin.org/articles/10.3389/fmed.2022.964099/full.

Citation: Frontiers Editorial Office (2022) Expression of Concern: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front. Med. 8:831449. doi: 10.3389/fmed.2021.831449

Received: 08 December 2021; Accepted: 13 December 2021;
Published: 17 January 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Editorial Office, ZWRpdG9yaWFsLm9mZmljZUBmcm9udGllcnNpbi5vcmc=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Expression of Concern: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

94% of researchers rate our articles as excellent or good

94% of researchers rate our articles as excellent or good